Antagonism of β3 adrenoceptor for the treatment of cancer immune tolerance
The invention relates to the use of beta-blocking compounds, in particular the antagonist of β3 adrenoceptor (β3-ARs), for the treatment of immune-tolerance associated with pathological states, such as cancer. The β3 adrenoceptor, up-regulated in a hypoxic environment, recruits in the tumor microenvironment the cells involved in immune-tolerance (MDSC e Treg) replacing the cells involved in immune-competence (CD8 and NK)
The compounds of the invention allow the development of immunomodulatory drugs for oncological purposes, since they are capable to counteract the immuno-tolerance generated by tumors. In particular, the invention focuses on the role of β3-ARs key receptors in the formation of a local and systemic micro-environment oriented towards immuno-tolerance, contributing significantly to decrease the immune system’s response. The creation of selective receptor antagonists to β3-ARs can therefore lead to the development of new drugs able to recognize, bind and inhibit the β3-ARs receptor, so as to restore the immune-surveillance compromised by the tumor.
- Development of new drugs;
- Treatment targeting;
- Drug targeting;
- Improvement of the Immuno-surveillance in cancer patients